New trends of acid-related diseases treatment

Tomoyuki Koike, Kenichiro Nakagawa, Takeshi Kanno, Katsunori Iijima, Tooru Shimosegawa

研究成果: Article査読

抄録

Acid-related diseases (ARD) including gatroesophageal reflux disease (GERD) and peptic ulcer disease (PUD) are treated by acid suppression drugs, especially proton pump inhibitor (PPI). Use of PPI as a first line therapy for ARD is recommended in various guidelines. Recently, vonoprazan, a new class of acid secretion inhibitor called potassium-competitive acid blocker (P-CAB) developed in Japan for the treatment of ARD. The drug is covered by the Japanese medical insurance for the treatment of ARD, and it is reported that Helicobacter pylori (HP) eradication rate with it is more than 90%.

本文言語English
ページ(範囲)1136-1146
ページ数11
ジャーナルNihon rinsho. Japanese journal of clinical medicine
73
7
出版ステータスPublished - 2015 7 1

ASJC Scopus subject areas

  • Medicine(all)

フィンガープリント 「New trends of acid-related diseases treatment」の研究トピックを掘り下げます。これらがまとまってユニークなフィンガープリントを構成します。

引用スタイル